Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic STS
Posted: Wed Feb 03, 2016 8:17 am
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Prof Ian Judson, MDcorrespondenceemail, Prof Jaap Verweij, PhD, Prof Hans Gelderblom, PhD, Prof Jörg T Hartmann, MD, Prof Patrick Schöffski, MPH, Prof Jean-Yves Blay, PhD, J Martijn Kerst, PhD, Prof Josef Sufliarsky, MD, Prof Jeremy Whelan, MD, Prof Peter Hohenberger, MD, Anders Krarup-Hansen, MD, Prof Thierry Alcindor, MD, Sandrine Marreaud, MD, Saskia Litière, PhD, Catherine Hermans, Prof Cyril Fisher, DSc, Prof Pancras C W Hogendoorn, PhD, Prof A Paolo dei Tos, MD, Prof Winette T A van der Graaf, PhD, for the European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group†
Need to search and view
Prof Ian Judson, MDcorrespondenceemail, Prof Jaap Verweij, PhD, Prof Hans Gelderblom, PhD, Prof Jörg T Hartmann, MD, Prof Patrick Schöffski, MPH, Prof Jean-Yves Blay, PhD, J Martijn Kerst, PhD, Prof Josef Sufliarsky, MD, Prof Jeremy Whelan, MD, Prof Peter Hohenberger, MD, Anders Krarup-Hansen, MD, Prof Thierry Alcindor, MD, Sandrine Marreaud, MD, Saskia Litière, PhD, Catherine Hermans, Prof Cyril Fisher, DSc, Prof Pancras C W Hogendoorn, PhD, Prof A Paolo dei Tos, MD, Prof Winette T A van der Graaf, PhD, for the European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group†
Need to search and view